Life Changing Daily Pill that Fights Cancer and Autoimmune Diseases

Invest Now for a Limited Time

Trethera News

Gloved hand of a scientist in a lab writing on a digital stilus with a digital pen.

Blue DNA illustration

Photo of a series of test tubes.

Scientific microscope with visual representation of DNA helix

Trethera Receives FDA Approval To Initiate TRE-515 Phase 1 Clinical Trial in Solid Tumors Monotherapy

Trethera Announces Jefferies & Company Chairman Emeritus Frank Baxter as Special Advisor

Trethera Announces Completion of $3.2 Million Seed Funding Round From Current Investors

February 24, 2021

Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 in the Treatment of Acute Disseminated Encephalomyelitis

January 7, 2021

Globally Renowned Research Scientist Dr. Michael Shepard Joins Trethera’s Scientific Advisory Board

December 8, 2020